Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.

Hylton N.

J Clin Oncol. 2006 Jul 10;24(20):3293-8. Review.

PMID:
16829653
2.

Dynamic contrast-enhanced magnetic resonance imaging in oncology.

Knopp MV, Giesel FL, Marcos H, von Tengg-Kobligk H, Choyke P.

Top Magn Reson Imaging. 2001 Aug;12(4):301-8. Review.

PMID:
11687716
3.

Molecular imaging of antiangiogenic agents.

Rehman S, Jayson GC.

Oncologist. 2005 Feb;10(2):92-103. Review.

4.

Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.

Padhani AR.

J Magn Reson Imaging. 2002 Oct;16(4):407-22. Review.

PMID:
12353256
5.

Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging.

Padhani AR, Leach MO.

Abdom Imaging. 2005 May-Jun;30(3):324-41. Review.

PMID:
15688112
6.
7.

Fundamentals of quantitative dynamic contrast-enhanced MR imaging.

Paldino MJ, Barboriak DP.

Magn Reson Imaging Clin N Am. 2009 May;17(2):277-89. doi: 10.1016/j.mric.2009.01.007. Review.

PMID:
19406359
9.

Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.

Choyke PL, Dwyer AJ, Knopp MV.

J Magn Reson Imaging. 2003 May;17(5):509-20. Review.

PMID:
12720260
10.

Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate.

Bonekamp D, Macura KJ.

Top Magn Reson Imaging. 2008 Dec;19(6):273-84. doi: 10.1097/RMR.0b013e3181aacdc2. Review.

PMID:
19512849
11.

Dynamic contrast-enhanced MRI in oncology drug development.

Cheng HL.

Curr Clin Pharmacol. 2007 May;2(2):111-22. Review.

PMID:
18690858
12.

Quantification of antiangiogenic and antivascular drug activity by kinetic analysis of DCE-MRI data.

Ferl GZ, Port RE.

Clin Pharmacol Ther. 2012 Jul;92(1):118-24. doi: 10.1038/clpt.2012.63. Epub 2012 May 16. Review.

PMID:
22588603
13.

Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging.

Kiessling F, Morgenstern B, Zhang C.

Curr Med Chem. 2007;14(1):77-91. Review.

PMID:
17266569
14.

Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy.

Padhani AR, Khan AA.

Target Oncol. 2010 Mar;5(1):39-52. doi: 10.1007/s11523-010-0135-8. Epub 2010 Apr 11. Review.

PMID:
20383784
15.

Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives.

Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C.

Crit Rev Oncol Hematol. 2009 Dec;72(3):217-38. doi: 10.1016/j.critrevonc.2008.07.012. Epub 2008 Aug 29. Review.

PMID:
18760935
16.

Magnetic resonance imaging as a biomarker in renal cell carcinoma.

Pedrosa I, Alsop DC, Rofsky NM.

Cancer. 2009 May 15;115(10 Suppl):2334-45. doi: 10.1002/cncr.24237. Review.

17.

Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI.

Taylor JS, Reddick WE.

Adv Drug Deliv Rev. 2000 Mar 15;41(1):91-110. Review.

PMID:
10699307
18.

Dynamic contrast-enhanced MR imaging in the evaluation of patients with prostate cancer.

McMahon CJ, Bloch BN, Lenkinski RE, Rofsky NM.

Magn Reson Imaging Clin N Am. 2009 May;17(2):363-83. doi: 10.1016/j.mric.2009.01.013. Review.

PMID:
19406364
19.

Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.

Schmidt GP, Kramer H, Reiser MF, Glaser C.

Top Magn Reson Imaging. 2007 Jun;18(3):193-202. Review.

PMID:
17762383
20.

Fundamentals of tracer kinetics for dynamic contrast-enhanced MRI.

Koh TS, Bisdas S, Koh DM, Thng CH.

J Magn Reson Imaging. 2011 Dec;34(6):1262-76. doi: 10.1002/jmri.22795. Epub 2011 Oct 3. Review.

PMID:
21972053

Supplemental Content

Support Center